Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat? by Aarts, F. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/80371
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS
Volume 24, Number 1, 2009
© Mary Ann Liebert, Inc.
DOI: 10.1089/cbr.2008.0521
Can Antibody Galactosylation Be Used to Improve
Radioimmunotherapy of Induced Peritoneal 
Carcinomatosis of Colonic Origin in the Rat?
Frits Aarts,1 Thijs Hendriks,1 Annemarie Eek,2 Wim. J.G. Oyen,2
Robert P. Bleichrodt,1 and Otto C. Boerman2
Abstract
In radioimmunotherapy (RIT), hematologic toxicity is the dose-limiting toxicity due to the long circulatory half-
life of the antibody. Although intraperitoneal (i.p.) RIT results in high uptake of i.p. growing tumors, the ra-
diolabeled antibody enters the circulation, resulting in bone marrow toxicity. Carbohydrate modification of an-
tibodies could induce accelerated clearance of the antibody via the hepatic asialoglycoprotein receptor, thereby
reducing exposure to normal tissues. In this study, we investigated whether galactosylation of an antibody in
a model of peritoneal carcinomatosis (PC) of colonic origin could be used to improve targeting of i.p. growing
tumors. Therefore, the biodistribution of the galactosylated and nongalactosylated anti-CC531 antibody, MG1,
after i.p. injection was determined in a model of peritoneal carcinomatosis of CC-531 colon tumors in Wag/Rij
rats. Uptake of the radiolabeled antibodies in the tumor and relevant organs was determined at 2, 4, 24, and
48 hours after injection. Galactosylation of the antibody did not affect the binding affinity of MG1. Remark-
ably, the uptake of Gal-MG1 in tumors was higher than that of MG1 at 2 and 4 hours after injection. After 24
and 48 hours, uptake of Gal-MG1 in tumor tissue was lower than that of MG1. Gal-MG1 cleared from the blood
within hours after administration. At 2–24 hours after administration, tumor-to-blood ratios obtained with Gal-
MG1 were significantly higher than those obtained with unmodified MG1. Antibody galactosylation resulted
in improved tumor-non-tumor ratios after i.p. injection in a model of PC. This could improve the efficiency of
RIT, especially in combination with short-lived nonresidualizing radionuclides.
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Introduction
Radioimmunotherapy (RIT) comprises the selective irra-diation of tumor cells with radiolabeled antitumor anti-
bodies (Abs). RIT has been shown to be an effective treat-
ment in hematologic malignancies.1 However, in solid
cancers, RIT is less effective, which is partly due to their in-
trinsic radioresistance and a limited uptake and penetration
of Abs in solid tumors.2 An inverse relation has been shown
to exist between the size of the lesion and the uptake of the
radiolabeled antibody.3 Therefore, RIT seems to be an at-
tractive adjuvant therapy after surgical debulking proce-
dures, leaving only a microscopic residual tumor.
We have shown previously that the adjuvant intraperi-
toneal (i.p.) administration of RIT after cytoreductive sur-
gery (CS) is an effective treatment for experimental peri-
toneal carcinomatosis (PC) of colonic origin.4,5 Survival in
Wag/Rij rats with i.p. CC531 (colon carcinoma) tumors im-
proved significantly when CS was followed by the i.p. ad-
ministration of RIT with 2 mCi of the 177Lu-labeled anti-
CC531 antibody, MG1. The effect was most explicit when
RIT was administered immediately after surgery. In addi-
tion, RIT was found to be at least as effective as hyperther-
mic i.p. chemotherapy (HIPEC), which is the current stan-
dard of care, while it resulted in significantly less
treatment-related toxicity.6
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In order to enhance the therapeutic efficacy of radiolabeled
Abs, different strategies have been pursued, ranging from
locoregional administration of these Abs, as described above,
to the application of Ab fragments and pretargeting sys-
tems.7 We studied galactosylation of the antitumor antibody
as a new method to enhance the efficacy of i.p.-applied RIT
for the treatment of i.p. tumors. After direct tumor targeting
following i.p. administration, this modification induces very
rapid blood clearance via the hepatic asialoglycoprotein re-
ceptor (AGPR). This could result in high tumor-to-blood and
tumor-to-non-tumor ratios.8,9 As a consequence of rapid
clearance, the radiation dose that is delivered to the bone
marrow will be reduced, thus lowering hematologic toxicity.
Ultimately, this effect would allow the administration of
higher doses of radioactivity and potentially increase the ef-
ficacy of RIT. To test this hypothesis, the tumor targeting and
uptake in nontarget tissues of i.p.-injected Gal-MG1 was
compared with that of nongalactosylated MG1 in Wag/Rij
rats with small-volume peritoneal CC-531 carcinomatosis.
Materials and Methods
Reagents
Antibody. The murine MG1 monoclonal antibody (mAb),
an anti-CC531 IgG2a mAb (Antibodies for Research Appli-
cations BV, Gouda, The Netherlands) specifically directed
against an 80-kDa cell-surface antigen expressed on CC531
cells, was used in these studies. The MG1 mAb localizes pref-
erentially in tumors when injected in rats bearing CC531 tu-
mors.10
Galactosylation. To galactosylate MG1, cyanomethyl-
2,3,4,6-tetra-O-acetyl-1-thio-beta-D-galactopyranoside
(CAGP, C-4141; Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands) was dissolved in methanol at a concentra-
tion of 34 mg/mL and mixed with an 0.1 volume of 0.1 M of
sodium methoxide, also in methanol. After 48 hours at room
temperature, the methanol was evaporated (Argon flow,
35°C) to dryness and the residue was dissolved in 1 mL of
0.025 M sodium borate buffer (pH 8.5), containing 5 mg of
MG1. After 2 hours at room temperature, the reaction mix-
ture was dialyzed against phosphate-buffered saline (PBS).
To determine the number of galactosyl groups that were
conjugated per MG1 molecule, the method described by
Dubois et al. was used, with minor modifications.11 To 0.1
mL of galactose solution (0.8–20 g), 0.1 mL of 5% phenol
solution was added and mixed. Then, 0.5 mL of concentrated
H2SO4 was added to the solution. The mixture was vortexed
and allowed to stand for 30 minutes at room temperature.
The galactosylated antibody solution (0.1 mL) was similarly
treated. Absorbance at 490 nm was measured with an Amer-
sham Pharmacia BioTech Benelux (Zwijndrecht, The Nether-
lands) Ultrospec 2000 spectrophotometer. It was determined
that 25 molecules of galactose were conjugated per MG1
molecule.
Radioiodination. Galactosylated MG1 was radioiodinated
with 125I (Amersham, Den Bosch, The Netherlands), while
the ungalactosylated MG1 was radioiodinated with 131I, us-
ing the iodogen method, as described previously.12 Briefly,
the antibody (1 mg) and the radioiodide (600 Ci) were in-
cubated at room temperature in PBS (pH 7.4) in an Eppen-
dorf tube (Omnilabo, Breda, The Netherlands), coated with
50 g of iodogen. After 10 minutes, the reaction was stopped
by adding 100 L of a saturated tyrosine solution. The ra-
dioiodinated antibodies were purified on a PD-10 column
(Amersham Biosciences, Uppsala, Sweden), eluted with PBS
and 0.5% bovine serum albumin (BSA). This resulted in a
specific activity of 0.56 Ci/g for MG1 and 0.48 Ci/g
for galactosylated MG1.
Competitive binding assay. To determine the effect of
galactosylation on the affinity of the MG1 antibody, the IC50
value of Gal-MG1 and MG1 was determined in a competi-
tive binding assay. Binding of the 125I-labeled MG1 was com-
peted by unlabeled nongalactosylated MG1 or Gal-MG1 and
in a concentration-dependent manner. 125I-labeled MG1 was
used as the tracer in this assay. Six-well Costar culture plates
(Corning Life Sciences B.V., Schiphol-Rijk, The Netherlands)
were seeded with CC531 cells and cultured until confluency.
The plates were washed twice with PBS. Then, 3 mL of bind-
ing buffer containing 50,000 cpm of 125I-MG1 with a serial
dilution (0 mg/mL to 1.5  107 mg/mL) of nonlabeled
MG1 or galactosylated MG1 in binding buffer was incubated
in the wells at 37°C for 1 hour. After incubation, the plates
were washed three times with PBS. Radioactivity in each
well was determined in a -counter (1480 Wizard; Wallac,
Turku, Finland). IC50 values of MG1 and Gal-MG1 were cal-
culated by nonlinear regression, using GraphPad Prism 4.0
(GraphPad Prism Software, San Diego, CA).
Model of peritoneal carcinomatosis
The syngeneic rat colon carcinoma cell line, CC531, origi-
nally induced in Wag/Rij rats by the intravenous injection
of 1,2-dimethylhydrazine,13 was cultured and maintained as
a monolayer in RPMI-1640 medium (GIBCO, BRL Life Sci-
ences Technologies, The Netherlands), supplemented with
10% fetal calf serum (FCS; GIBCO), 2 mM L-glutamine, peni-
cillin [100 U/mL], and streptomycin [100 g/mL] at 37°C in
a humidified atmosphere with 5% CO2. Tumor cells were
harvested from culture flasks with 0.25% trypsin and resus-
pended in RPMI-1640 medium to a concentration of 1  106
cells/mL. Two (2) mL of this cell suspension was injected
i.p., as previously described.14 Male WAG/Rij rats (10–12
weeks old, body weight 240–260 g; Harlan Horst, The
Netherlands) were housed under nonsterile standard condi-
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FIG. 1. Competitive binding assay showing the affinity of
both galactosylated and ungalactosylated MG1 for CC531
cells. , MG1; , Gal-MG1.
tions (temperature, 20–24°C; relative humidity, 50%–60%;
12-hours light and dark cycle) in filter-topped cages (2–3 rats
per cage) with free access to food (Ssniff; Bio Services Uden,
The Netherlands) and water. Rats were accustomed to labo-
ratory conditions for at least 1 week before experimental use.
All experiments were approved by the local Animal Welfare
Committee of Radboud University (Nijmegen, The Nether-
lands) and were carried out in accordance with the Dutch
Animal Welfare Act of 1997.
Biodistribution
First, the optimal CAGP:IgG conjugation ratio to prepare
the Gal-MAb conjugates was determined by using the unre-
lated anti-CAIX MAb, G250. G250-Gal conjugates were pre-
pared at four different molar CAGP:IgG conjugation ratios
(60:1 to 3000:1). The four Gal-G250 conjugates were labeled
with I-125 and injected into rats via the tail vein. All Gal-
G250 conjugates cleared rapidly from the (blood level 0.7%
injected dose per gram [ID/g] at 5 minutes postinjection).
Based on these studies, the lowest conjugation ratio (1:60)
was used to prepare the Gal-MG1 conjugate in the biodis-
tribution studies.
The biodistribution of galactosylated MG1 labeled with
125I and nongalactosylated MG1 labeled with 131I in Wag/Rij
rats with i.p. growing CC531 tumor nodules was determined
at 2, 4, 24, and 24 hours (n  5/group) after i.p. injection.
Both radiolabeled Abs (1 mL/rat, 8 Ci 131I-MG1/rat, 9 Ci
125I-Gal-MG1/rat) were administered simultaneously. At
dissection, samples of the tumor, blood, liver, spleen, kid-
neys, intestine, lung, and muscle were removed and imme-
diately weighed. Radioactivity was measured in a well-type
-counter (Wizard; Pharmacia-LKB). To correct for physical
decay and to calculate the uptake of the radiolabeled anti-
body in each sample as a fraction of the injected dose, ali-
quots of the injected dose were counted simultaneously. The
uptake was expressed as the %ID/g.
Statistical analysis
Statistical analysis was performed by using SPSS (SPSS
Inc., Chicago, IL) software and Graphpad Prism, version 4.0
(Graphpad Software Inc., San Diego CA) for analysis. For
single comparison, the paired t-test was used. IC50 values of
the MG1 were calculated by nonlinear regression, using
GraphPad Prism (GraphPad Software).
Results
Reagents
Affinity. The affinity of the galactosylated MG1 was deter-
mined in a competitive binding assay. The results are shown
in Figure 1. Binding of 125I-MG1 to CC531 cells was com-
peted for by both Gal-MG1 and MG1 in a concentration-de-
pendent manner. Both IC50 values were in the nanomolar
range, with 1.6 nM for MG1 and 1.2 nM for Gal-MG1.
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FIG. 2. Biodistribution results of Gal-MG1 and MG1 at (A) 2, (B) 4, (C) 24, and (D) 48 hours after intraperitoneal admin-
istration, expressed as the mean percent injected dose per gram of tissue. Bars indicate the standard error of the mean. 
MG1; Gal-MG1.
A B
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Biodistribution
The results of the biodistribution studies are summarized
in Figure 2A–2D. There was a preferential uptake of both ra-
diolabeled antibody preparations in the i.p. tumors. At 2 and
4 hours postinjection, the uptake of Gal-MG1 in tumor tis-
sue (14.0  7.5 and 9.9  3.0 %ID/g, respectively) was sig-
nificantly higher than that of the ungalactosylated MG1
(5.4  1.9 and 4.3  1.0 %ID/g; p  0.04). Tumor-to-blood
ratios at 2 and 4 hours after injection for Gal-MG1 were 10-
fold higher than those obtained with ungalactosylated MG1
(32.4  18.9 vs. 3.2  1.48 at 2 hours and 18.7  5.51 vs. 1.9 
0.59 at 4 hours; p  0.0001). At 24 and 48 hours after ad-
ministration, the uptake of Gal-MG1 in tumor tissue (0.7 
0.2 %ID/g at 24 hours and 0.2  0.1 %ID/g at 48 hours)
tended to be lower than that of ungalactosylated MG1 (2.6 
1.0 %ID/g, p  0.06, and 1.5  1.3 %ID/g, p  0.10, respec-
tively). Although the tumor uptake of the galactosylated Ab
was lower at 24 and 48 hours after administration, the tu-
mor-to-blood ratios for Gal-MG1 remained significantly
higher at 24 hours (2.70  0.81) than those obtained with un-
galactosylated MG1 (1.04  0.39; p  0.04). After 48 hours,
there was no significant difference in tumor-to-blood ratios.
In addition, uptake of Gal-MG1 in all normal tissues, except
the liver, was lower than that of MG1 at 2 and 4 hours after
injection. One (1) and 2 days after administration, liver up-
take was lower for Gal-MG1, as compared to MG1 (Figure
2C and 2D). The uptake in nontarget organs, such as mus-
cle, lung, spleen, and kidneys, was low for both Abs, albeit
lower for Gal-MG1 after 24 and 48 hours.
The total area under the curve (AUC) for Gal-MG1 for the
tumor was 192 %ID/g  h, as compared to 90 %ID/g  h for
ungalactosylated MG1. For the blood, the total AUC for the
galactosylated Ab was 7.9 %ID/g  h, as compared to 24.5
%ID/g  h for MG1. The ratio of total AUC of Gal-MG1 in
the tumor/AUC for blood was 24.3, as compared to 3.7 for
the ungalactosylated MG1.
Discussion
The aim of this study was to investigate whether galacto-
sylation of antitumor antibody MG1 could improve the pref-
erential targeting of i.p. tumors in a rat model. The rationale
for using a carbohydrated antitumor antibody is that galac-
tosylated antibodies clear very rapidly from the blood via the
hepatic asialoglycoprotein receptor (AGPR), resulting in low
blood levels.8,9 In cases of i.p. tumors, this could result in op-
timal tumor targeting after i.p. administration with concomi-
tant rapid clearance when the antibody enters the circulation.
Indeed, at all the time points after i.p. injection, blood lev-
els of Gal-MG1 were significantly lower than the blood lev-
els of MG1. Ong et al. investigated the administration of
galactosylated Abs in a model of an i.p. ovarian cancer cell
line.15 The investigators described a tumor uptake of 4.3
%ID/g 28 hours after injection with a peritoneal retention of
the administered Ab of 10% 24 hours after administration.
In these experiments, however, peritoneal clearance was dis-
turbed by the application by Freund’s adjuvant, causing a
major inflammatory response, thus not resembling normal
physiology. Sharma et al. used a model of subcutaneously
growing human colon cancer xenografts in mice.16 The in-
vestigators used blocking agents to obtain a prolonged cir-
culation of the galactosylated antibodies for the duration of
8 hours. This resulted in tumor-to-blood ratios of 45:1.
Galactosylation of MG1 did not affect the affinity of the
Ab for the MG1 antigen. Remarkably, within the first 24
hours after administration, tumor uptake of the Gal-Ab was
significantly higher (2.6-fold at 2 hours and 2.3-fold at 4
hours after administration) than that of the nongalactosy-
lated antibody. The higher tumor uptake could be due to a
longer i.p. retention time of the Gal-Ab. The more negative
charge of the Gal-MG1 could result in a slower transit from
the i.p. cavity to the circulation. The lower tumor uptake of
the galactosylated MG1 after 24 and 48 hours is due to the
reduced blood levels of Gal-MG1. We assumed that anti-
body uptake in i.p. tumors after i.p. injection was the result
of delivery, both directly from the peritoneal cavity as well
as via the i.v. route. After 24 hours, most of the galactosy-
lated Abs had cleared from the peritoneal cavity. As a con-
sequence of galactosylation, the antibody would have
cleared from the circulation, whereas the ungalactoslated
antibody would still circulate at relatively high levels in the
blood.17–19
Despite the significantly lower tumor uptake of Gal-MG1
after 24 and 48 hours, the total AUC of the tumor was higher
for the galactosylated antibody. Moreover, the ratio of
AUC(tumor)/AUC(blood) for Gal-MG1 was 7 times higher than
the ratio for ungalactosylated MG1. Thus, when normalized
for the AUC of the blood, the AUCtumor of the galactosylated
Ab was 7 times higher. Bone marrow toxicity is related to
the AUCblood. The AUCtumor can be normalized for AUCblood,
and thus the comparison for both AUC for tumor at an eq-
uitoxic bone marrow dose can be determined. This would
indicate that the radiation dose of 131I-Gal-MG1 to the tumor
is approximately 7 times higher than that of 131I-MG1 at an
equitoxic dose. Considering the high initial tumor uptake,
the high tumor-to-non-tumor ratios after i.p. injection of Gal-
Ab and the favorable normalized AUCtumor, RIT, using these
modified Abs, seems feasible. In this model, tumor uptake
peaks within 24 hours after i.p. administration. As a result,
the favorable effect of the galactosylated Ab could be more
pronounced when other radionuclides with relatively short
half-lives and nonradiometals were used. In addition, since
clearance of galactosylated antibodies is via the hepatic
AGPR, the use of residualizing radiometals, such as 177Lu
and 90Y, could result in increased radiation dose to the liver.
Almqvist et al. showed excellent tumor targeting of subcu-
taneous colon tumors in a mouse model with a low liver up-
take of the 211At-labeled antibody A33.20 211At is a non-
residualizing radionuclide with a relatively short half-life
(7.2 hours) and has exquisite characters for RIT of i.p. tumors
with galactosylated antibodies.
Conclusions
Therefore, the i.p. application of RIT for the treatment of
peritoneal carcinomatosis, using galactosylated antibodies,
needs further exploration.
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